<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007316.ref024">
 <label>24</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Chang</surname>
   <given-names>LJ</given-names>
  </name>, 
  <name>
   <surname>Dowd</surname>
   <given-names>KA</given-names>
  </name>, 
  <name>
   <surname>Mendoza</surname>
   <given-names>FH</given-names>
  </name>, 
  <name>
   <surname>Saunders</surname>
   <given-names>JG</given-names>
  </name>, 
  <name>
   <surname>Sitar</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Plummer</surname>
   <given-names>SH</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial</article-title>. 
  <source>Lancet (London, England)</source>. 
  <year>2014</year>;
  <volume>384</volume>(
  <issue>9959</issue>):
  <fpage>2046</fpage>â€“
  <lpage>52</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61185-5</pub-id>
  <?supplied-pmid 25132507?>
  <pub-id pub-id-type="pmid">25132507</pub-id>
 </mixed-citation>
</ref>
